SignatureFD’s Anixa Biosciences ANIX Stock Holding History

SignatureFD’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-57	Closed	-$186	–	3132
2023 Q3	$186	Hold	57	–	–	﹤0.01%	3101
2023 Q2	$182	Buy	+57	New	+$220	﹤0.01%	3145

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MWM

Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SignatureFD's ANIX Position: Q4 2023 in Review

SignatureFD sold out of Anixa Biosciences (ANIX) in Q4 2023, closing a stake of 57 shares — an estimated $186 sold.

SignatureFD first reported a position in ANIX in Q2 2023 and held it in 2 quarters. The position peaked at $186 in Q3 2023. 55 funds tracked by Wall St. Rank hold ANIX as of Q4 2023.

SignatureFD reported no remaining Anixa Biosciences position as of Q4 2023 after selling out during the quarter.
SignatureFD sold 57 Anixa Biosciences shares in Q4 2023, an estimated $186.
SignatureFD first reported a position in Anixa Biosciences in Q2 2023 and held it in 2 quarters.
SignatureFD's Anixa Biosciences position peaked at $186 in Q3 2023.
55 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.